MiniMed Group, Inc. MMED PHARMA
Company Overview
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, such as insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera Sync, or Guardian 4 sensor, and wraparound applications and services. It also offers CareLink, a software platform that provides support for person with diabetes, their caretakers, and HCPS. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California. MiniMed Group, Inc. operates as a subsidiary of Medtronic plc.
Why Investors Should Care
Revenue has grown at a 12.1% CAGR over the past five years.
Recent Developments
- Apr 2026 Revenue of $3.10B (+14.3% YoY); net profit $-333.00M.
- Trailing 12 Months Year-on-year growth — revenue +16.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 12.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 12.09% |
| 1 Year: | 16.60% |
Stock Price Performance
| 1 Year: | +26.12% |
| 6 Months: | +29.56% |
| 3 Months: | +56.72% |
| 1 Month: | +18.98% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- RSI (14)71.33 · Overbought
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 12.1% over 5 years.
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MMED MiniMed Group, Inc. PHARMA | 23.32 | -20.82 | $6.56B | 0.00% | -4.84% | -8.66% | 12.09% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jan 2025 | Jan 2026 |
|---|---|---|
| Revenue | 687.00M | 790.00M |
| Gross Profit | 395.00M | 362.00M |
| Operating Income | 21.00M | -100.00M |
| Net Income | -10.00M | -119.00M |
| Diluted EPS | -0.04 | -0.47 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Revenue | 2.47B | 2.71B | 3.10B |
| Gross Profit | 1.44B | 1.53B | 1.68B |
| Operating Income | -69.00M | -146.00M | -190.00M |
| Net Income | -112.00M | -213.00M | -333.00M |
| Diluted EPS | -0.44 | -0.84 | -1.30 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Apr 2023 | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|---|
| Total Assets | - | - | 4.20B | 4.63B |
| Total Equity | 3.40B | 3.45B | 3.33B | 3.61B |
| Cash & Equivalents | - | - | 11.00M | 298.00M |
| Total Liabilities | - | - | 871.00M | 1.02B |
| Current Liabilities | - | - | 710.00M | 702.00M |
Cash Flows (Annual)
Figures in USD.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Operating Cash Flow | 41.00M | 140.00M | -197.00M |
| Investing Cash Flow | -157.00M | -193.00M | -233.00M |
| Financing Cash Flow | 112.00M | 10.00M | 716.00M |
| Capital Expenditure | -148.00M | -193.00M | -223.00M |
| Free Cash Flow | -107.00M | -53.00M | -420.00M |
Ratios (Annual)
Figures in %.
| Metric | Apr 2024 | Apr 2025 | Apr 2026 |
|---|---|---|---|
| Gross Margin % | 58.2% | 56.3% | 54.2% |
| Operating Margin % | -2.8% | -5.4% | -6.1% |
| Net Margin % | -4.5% | -7.8% | -10.7% |
| ROE % | -3.2% | -6.4% | -9.2% |
| ROCE % | - | -4.2% | -4.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Massachusetts Financial Services Co. | 2.96% | 8.33M | $181.61M |
| 2 | Millennium Management Llc | 1.09% | 3.06M | $66.69M |
| 3 | Citadel Advisors Llc | 1.02% | 2.87M | $62.44M |
| 4 | Longaeva Partners L.P. | 1.00% | 2.81M | $61.29M |
| 5 | Blackrock Inc. | 0.71% | 2.00M | $43.50M |
| 6 | Sessa Capital IM, L.P. | 0.71% | 2.00M | $43.58M |
| 7 | NORGES BANK | 0.70% | 1.96M | $42.73M |
| 8 | Rock Springs Capital Management, LP | 0.54% | 1.52M | $33.12M |
| 9 | ExodusPoint Capital Management, LP | 0.51% | 1.44M | $31.31M |
| 10 | FMR, LLC | 0.38% | 1.08M | $23.55M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MMED
MiniMed (MMED) lifts sales 16.6% but highlights $157M royalty and pump litigation - Stock Titan
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQM0JGRGVCb1JCWUxiaTVTazRDemxSM0ZXQ2ZKSHViOEI0ZkxHMnUtQmJkMFNLRHBqSnNqeVB1aW9rdWtMNGFMSzItRnpZVUlKOVo4Q3NtVUtmMWhweGtIdlVaZ05kUHRyV3hEZ2hnZElKRGwzcngtUXBQX3lkclNyQml2NW9rRHpLZWJJLU…
Why Did PFE, MMED, DE Stocks Surge To 52-Week Highs Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNUVFBaWYzQ2VpWFJIWGtFUG52dzFDOGc0Tm1HcWM4VGtjc09GVmNWVXRscDNVUTVfM0RqdXNRRENvRm9Lak9sY21CQllaWTlTYnB2dThfek5NWkZ1VWQzNDY0MW9XbldZWEhERDRZYWIzUTBqVGswSEJPMjZ1SEJNc05vbWF4cm5hMmcwN1…
MiniMed Group (MMED) Stock Looks Below Fair Value While Growth Questions Linger - simplywall.st
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxQc1ZkcWdhcl9JYlUzTGpWczhWN2IxMEJOUHNQM2lDbWc4ZFhVNzU2dC1UaHFBaFRIUkxmd0EtYVhpZzlUa3loUUk1YTU0OXd2Vy1ZeGkyYzh5TlBYNWl2Y2FBZW9WeHpPeTFRb3c3aGM5UEpBM29QQ0VoTDZ4dUtTcGhnSjhMZGxXUl8tTW…
MiniMed Group, Inc. 2026: Revenue $843M, EPS $0— 10-Q Summary - tradingview.com
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxON21pdHJ2cUk3YThvaGtoQjVrZm0wOWs3Tk0wN094OVNiTmsyNHV3Y1V6S3QtR29CNWQwbF9TdldmcmJnUHRKa1FwS3R4UFV5Q2haeDFCRzIwejhKbHhQRlJ3ZWx0Q09ialhIazFnU1MtVFdCSDdVNHNMajhtTS1UN2NUdU00RDBSbG1ZRm…
Is It Time To Revisit Minimed Group (MMED) After Recent Share Price Weakness? - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNV2lSNkNDMWJtdUtLM0FSNld2d085RmdhZVpBWmh0Qy04TnhrWmp3VXdIZVNOV3JGdVlPTnhER1hrcDVIaUMzMmNHRW52NE1JRDZoS01vRW8yejJPSlVfQmFnb09oMGo3aTQ1YU03dXBWT2xoSUE1YzV1VGZFMms1TTNzR3NHWWhWeW9uel…
Club Med: betting on a return to the stock market after a mixed first experience - luxus-plus.com
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNSnRBdUlrWFByVUZoSTdzQzBIV3BLWG8wdDdVUExRQ2cydUpJbTRtTVduWjRId0xsRlFCMjl6M3pYZG1OR21LMG5OOWd6MkQ1TGtZMHlzYUVGX0hrT3FpZDMzbkhPRG5yOUZCWWVaanNGekRSUGlGd1Z6NERWLTg5TC1aMEdRNldfZXl1Nz…
MMED — Frequently Asked Questions
What is the current share price of MiniMed Group, Inc. (MMED)?
As of 2026-09-19 21:16 PDT, MiniMed Group, Inc. (MMED) trades at $23.32 on NasdaqGS. Its 52-week range is $10.80 to $23.84.
What is the market capitalisation of MMED?
MiniMed Group, Inc. (MMED) has a market capitalisation of $6.56B on NasdaqGS.
What is the P/E ratio of MMED?
MMED trades at a trailing price-to-earnings (P/E) ratio of -20.82. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.69.
What is the return on equity (ROE) of MMED?
MMED has a return on equity (ROE) of -8.66%. Its return on capital employed (ROCE) is -4.84%.
Is MMED a good stock to buy?
This page provides a data-driven analysis of MiniMed Group, Inc. (MMED), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.